(Q34523871)

2 August 2017

0 references

1 reference

title

Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management (English)

1 reference

2 August 2017

1 reference

1 reference

1

Stuart Stoloff

1 reference

2 August 2017

Kim Poinsett-Holmes

2

1 reference

2 August 2017

Paul M Dorinsky

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

22

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

212-226

1 reference

An economic evaluation of asthma in the United States

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Multiple dose regimens. Impact on compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

The complexity of treatment adherence in adults with asthma: challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Airway inflammation in mild intermittent and in persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Fluticasone propionate compared with theophylline for mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Potential masking effects of salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Asthma. From bronchoconstriction to airways inflammation and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Tissue remodeling as a feature of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Salmeterol versus theophylline in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.3.212.33550

10.1592/PHCO.22.3.212.33550

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference